Wegovy frees 40% of children from obesity in phase 3 trial

The wire

1. 01Novo Nordisk reported phase 3 results in which about 40% of children treated with Wegovy no longer met criteria for obesity at the end of the trial.
2. 02Pediatric obesity prescribing remains contested, and a responder figure of this size gives clinicians a concrete number to weigh against long-term treatment duration.
3. 03Full endpoint detail, safety data and durability after stopping treatment matter more than the headline responder rate; the sponsor generated the results.

From the source

Novo Nordisk’s Wegovy helps free 40% of kids from obesity in phase 3 trial